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Rosmarinic acidAllergic asthma has emerged as an important public health problem of urban populations in developed coun-
tries. Very often herbal medicine is used to treat this widespread disease, due to the lack of efﬁcacy and the
important side effects related to the classical drugs in use. Along this line, Ocimum gratissimum (Og) is a plant
widely used in Brazilian folk medicine to treat inﬂammatory disorders, such as asthma.
In the present study we evaluated the immunomodulatory effects of Og and rosmarinic acid (RA, a polyphe-
nolic compound) in a murine model of respiratory allergy induced by the Blomia tropicalis (Bt) mite. The re-
spiratory allergy was induced in A/J mice by administration of Bt extract and the treatment was done using
25, 50 or 100 mg/kg of an Og methanolic extract or using 2, 20 or 200 mg/kg of RA. We then evaluated the
changes induced by these drugs on immunological parameters related to the allergic process, which are
up-regulated in this allergic model. The treatment of animals with 100 mg/Kg Og and 200 mg/Kg RA led to
a signiﬁcant reduction in the numbers of leukocytes/eosinophils in bronchoalveolar lavage (BAL); eosinophil
peroxidase activity in BAL; presence of mucus in respiratory tract, histopathological changes in the lung, and
IL-4 in BAL. These results suggest that the methanolic extract of Og and the polyphenol RA have therapeutic
potential in this murine model of respiratory allergy to a clinically relevant human sensitizer allergen.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Asthma is now one of the commonest chronic diseases in the
world, affecting over 300 million people, and its prevalence is rising,
particularly in developing countries [1]. The prevalence of asthma in
Brazil, where antigens from the Blomia tropicalis house dust mite
are important sensitizing agents [2], is the 8th highest in the world
[3]. Approximately 5–10% of patients have uncontrolled disease, de-
spite taking inhaled therapy. These patients use a disproportionate
amount of healthcare resources, as they are admitted to hospital, con-
sume costly medication, and miss working days [4].
Although there are wide variations in the reported use of comple-
mentary and alternative medicine (CAM), a reasonable estimate is
that up to 30% of adults and 60% of children with asthma in the USA
are currently using some form of CAM to treat their condition [5].ulação, Instituto de Ciências da
, CEP 41110-100, Salvador, BA,
eiredo).
evier OA license.Historically, herbal medicine has a great importance in the treat-
ment of asthma. Various derivatives frommedicinal plants were iden-
tiﬁed as antiasthmatic medicines, and some of their mechanisms of
action were very well studied, such as those of α2 agonists, anti-
cholinergics, methylxanthines and chromones [6]. The understanding
of the chronic inﬂammatory scenario found in the airways of asth-
matic patients led to the glycocorticoids being the gold standard
drug in the treatment of allergic asthma [7]. The main disadvantage
of these drugs is their undesirable side effects.
Based on the lack of an effective drug for asthma treatment without
signiﬁcant side effects, an ethnopharmacological surveywas conducted
by our research group in the city of Salvador, Bahia, Brazil, in order to
ﬁnd out the main natural products administered for the treatment of
asthma in children, aiming at identifying plant species that could be
the object of future studies as source of anti-asthmatic drugs [8].
One of this species was Ocimum gratissimum Linn (Labiatae),
which is widely distributed in the tropics, is commonly used in folk
medicine and has scientiﬁcally conﬁrmed biological properties,
such as antinociceptive [9], spasmolytic [10] and antibacterial [11]
activities. Phytochemical studies revealed that O. gratissimum (Og)
is rich in polyphenols, such as rosmarinic acid (RA) [12], which has
127R.S. Costa et al. / International Immunopharmacology 13 (2012) 126–134recently been shown to have immunomodulatory activity, by sup-
pressing T-cell receptor (TCR) signaling [13]. The rosmarinic acid
from another plant species, Perilla frutescens, was able to prevent
an eosinophilic airway inﬂammation in mice. These effects were as-
sociated with inhibition of the local expression of Th2 cytokines
and chemokines [14].
Based on that, the objective of the present study, therefore, was to
evaluate the effect of Og and the polyphenolic phytochemical RA in a
murine model of respiratory allergy to B. tropicalis mite extract (Bt),
and to investigate some of the immunological phenomena modulated
by Og and RA, in order to elucidate the mechanism by which they
may be exerting their effect on experimental allergy.
2. Materials and methods
2.1. Animals
Male AJ mice (25–30 g) were used throughout the study. Ani-
mals were maintained with free access to food and water. They
were obtained from the animal facilities of the Fundação Oswaldo
Cruz, Bahia, Brazil. Groups of 5 animals were used in each experi-
ment. All the experimental procedures were approved by the Ethi-
cal Committee for Use of Experimental Animals of the Faculdade de
Odontologia, Universidade Federal da Bahia, Brazil (protocol num-
ber: 02/09) and conducted according to international standards
(http://grants.nih.gov/grants/olaw/GuideBook.pdf;http://ec.europa.
eu/environment/chemicals/lab_animals/legislation_en.htm).
2.2. B. tropicalis extract
The B. tropicalismites were cultivated in a ﬁsh food-containing stan-
dardized environment, puriﬁedwith saturatedNaCl and lysed in 0.15 M
phosphate-buffered saline, pH 7.4 (PBS), in a blender (51BL30; Waring
Commercial, Torrington, CO, USA). After several centrifugations with
ether (9000 g for 10 min), for removal of lipids, the protein content
was determined by Lowry's method [15] and the extract was stored at
−20 °C until use. The B. tropicalis extract (Bt) was standardized by de-
termining the Blo t 5 allergen concentration using a commercial capture
ELISA (INDOOR Biotechnologies, Charlottesville, VI, USA). All used Bt
batches contained 30–40 ng of this allergen per μg of protein.
2.3. O. gratissimum Linn. and its polyphenolic phytochemical rosmarinic
acid
The methanolic (Og) and hexanic (OgHE) extracts of Og were
prepared according to a technique previously described by Estrada-
Soto and colleagues [16]. Og leaves were obtained at the Laboratório
de Tecnologia Farmacêutica (LTF), Federal University of Paraíba,
Brazil, and kept in a cool and airy environment for ﬁfteen days for dry-
ing. The dry plantmaterial was pulverized and crude extract were pre-
pared by successive maceration process using methanol and hexane
(3 times for 72 h at room temperature). After ﬁltration, extracts
were concentrated in vacuum at 40 °C. Rosmarinic acid (RA) or [(R)-
O-(3,4-dihydroxycinnamoyl)-3-(3,4-dihydroxyphenyl) lactic acid
3,4-dihydroxycinnamic acid (R)-1-carboxy-2-(3,4-dihydroxyphenyl)
ethyl ester-C18H16O8] was purchased from Sigma-Aldrich (catalog
# 536954).
2.4. Standardization of O. gratissimum Linn. extract
The Og extract was standardized in terms of RA concentration by
high performance liquid chromatography, with ultraviolet light de-
tection at 330 nm, using a C18 column (250×4.6 mm ID, 5 μm parti-
cle size) and a C-18 pre-column (Phenomenex, Torrance, USA).
The mobile phase consisted of water acidiﬁed to pH 3.2 with for-
mic acid (A) and acetonitrile (B) at a ﬂow rate of 0.8 mL/min. Thefollowing gradient elution method was used for separation: 85% to
75% of A in 18 min, 75% to 45% of A in 7 min, 45% to 15% of A in
5 min, 15% to 85% of A in 5 min. A 20 μL sample was injected and
the detection of RA was performed using light with a wavelength of
330 nm [12]. A control RA solution was injected at a concentration
of 10.4 μg/mL.
2.5. Sensitization and challenge with B. tropicalis antigen
The murine model of respiratory allergy was induced as we previ-
ously described [17]. Brieﬂy, A/J mice (n=5) were initially sensitized
with two subcutaneous injections (day 0 and day 7) of Bt (10 μg of
protein), adsorbed to 4 mg/mL of Al(OH)3 in saline (Fig. 1). Twenty-
four hours after the last subcutaneous injection, the animals received
three intranasal immunization boosters/challenges with Bt (10 μg/
instillation) every other day, and, two days after the last immuniza-
tion booster/challenge, they received a ﬁnal intranasal challenge
with 10 μg of Bt (Fig. 1). A negative control group received saline in
both sensitization and challenge procedures. Twenty-four hours
after the last challenge, the animals were euthanized with intraperi-
toneal injections of xilazine and ketamine (40 mg/kg/body weight).
2.6. Treatment with O. gratissimum Linn. and rosmarinic acid
The different groups were treated daily from the 8th to the 14th
day of the experimental protocol, one hour after the intranasal chal-
lenges in the 8th, 10th, 12th, and 14th days (Fig. 1). The animals
were treated orally with 25, 50 or 100 mg/kg of Og and, intraperito-
neally, with 2, 20 or 200 mg/kg of RA [18] or orally/intraperitoneally
with 3 mg/kg of Dexametazone (Dex). The RA was not administered
orally due to the high rates of hydrolysis (up to 99%) held by the in-
testinal ﬂora [19]. The groups of animals were named as: Control,
non-sensitized and saline-treated mice; Bt, Bt-sensitized mice; Bt/
Og25; Bt/Og50; Bt/Og100, Bt-sensitized and 25, 50 or 100 mg/kg of
Og-treated mice, respectively; Bt/RA2; Bt/RA20; Bt/RA200, Bt-
sensitized and 2, 20 or 200 of RA-treated mice; Bt/Dex, Bt-sensitized
and Dex-treated mice.
2.7. Bronchoalveolar lavage (BAL)
The trachea was cannulated and the lungs were carefully washed
three times with 0.5 mL of PBS containing 1% of bovine serum albu-
min (BSA). The total number of leukocytes in the BAL was immediate-
ly determined in a hemocytometer, using Trypan blue. Differential
cell counts were obtained by using May–Grunwald–Giemsa-stained
cytospin preparations. A differential count of at least 100 cells was
made in a blind fashion in accordance with standard morphologic
criteria.
2.8. Eosinophil peroxidase (EPO) activity
The EPO activity in the cells obtained from the BAL was measured
according to a previously described method [20]. Brieﬂy, cell suspen-
sions were frozen and thawed three times in liquid nitrogen. After
centrifugation at 4 °C for 10 min at 1000 g, the cell lysates were
placed into wells of 96-well plates (75 μL/well), followed by the addi-
tion of 150 μL of the chromogen and substrate solution (1.5 mmol/L of
o-phenylenediamine and 6.6 mmol/L of H2O2 in 0.05 mol/L Tris–HCl,
pH 8.0). After 30 min at room temperature, the reaction was stopped
with the addition of 75 μL of 0.2 mol/L citric acid, and the absorbance
of the samples determined at 492 nm in an ELISA reader.
2.9. Levels of IL-4 in the bronchoalveolar lavage
The concentrations of IL-4 in the BALwere quantiﬁed by a standard
ELISA, as recommended by the manufacturer (BD Pharmingen, USA).
Fig. 2. Chromatogram of samples subjected to high performance liquid chromatography. Ab
anol extract. (B) Chromatogram of rosmarinic acid. (C) Chromatogram of O. gratissimum he
Sensitization with Bt by the subcutaneous route
Challenge with BtE by the intranasal route
Treatment with OgME or RA
Euthanasia
[D0] [D7] [D8] [D9] [D10] [D11] [D12] [D13][D14] [D15]
Fig. 1. Experimental protocol for induction of respiratory allergy using aluminum
hydroxide-adsorbed Blomia tropicalis extract (Bt) and assessment of the treatment with
O. gratissimum methanolic extract (Og, 25, 50 or 100 mg/kg, orally) and rosmarinic acid
(RA, 2, 20 or 200 mg/kg, intraperitoneally). [D0] to [D15], days 0 to 15 of experiments.
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The degree of peribronchiolar and perivascular inﬂammation was
evaluated as described previously [14]. Brieﬂy, lung tissues were ﬁxed
by inﬂation with freshly prepared 10% (v/v) paraformaldehyde. The
specimens were dehydrated and embedded in parafﬁn. Tissue sec-
tions (5 μm) were stained with hematoxylin and eosin, for the assess-
ment of cellular inﬁltration under optical microscopy with 200×
magniﬁcation. The data on quantiﬁcation of lung inﬂammation were
acquired using the software Image-Pro Plus Version 6.1 (Media
Cybernetics, San Diego, CA, USA) using the inﬂammatory area index.sorbance at 330 nm is shown at the Y axis. (A) Chromatogram of O. gratissimum meth-
xane extract. Retention times are shown above peaks in (A) and (B).
129R.S. Costa et al. / International Immunopharmacology 13 (2012) 126–134Afterwards, we used the average from each animal/slide. Additional-
ly, tissue sections were stained with periodic acid Schiff to assess
mucus presence. A quantitative digital morphometric analysis was
performed as described previously [17].2.11. Measurement of anti-Bt IgE antibody levels in the BAL
Antibody levels were determined by ELISA using samples col-
lected 24 h after the last Bt-challenge. In brief, wells of a 96-well
microtitre high-binding plate (Costar) were coated with Bt
(100 μg/mL) overnight, at 4 °C. The wells were washed 3 times
with PBS containing 0.05% Tween 20 (PBS-T) and blocked during
1 h with PBS-T containing 10% fetal calf serum (FCS) at room tem-
perature (RT). After several washes with PBS-T, the mouse sera
were added and incubated overnight at 4 °C. After this incubation
period and washes, a biotin-conjugated rat anti-mouse IgE (BD
Pharmingen, San Diego, CA, USA) was added in each well and incu-
bated during 1 h at RT. A solution of avidin-horseradish peroxidase
was then added to each well for 30 min. After washing, a solution
containing 3,3′,5,5′-tetramethylbenzidine and hydrogen peroxide
was added and incubated during 30 min at RT and the reaction
was stopped with 4 M sulfuric acid.2.12. Statistical analysis
The one-way analysis of variance (ANOVA) and Tukey's post-test
(for data with normal distribution) were used to determine the statis-
tical signiﬁcance between the experimental groups. Differences in p
values≤0.05 were considered statistically signiﬁcant. Each experi-
ment was repeated at least two times.Fig. 3. Effect of treatment with O. gratissimum methanolic extract (Og) and with rosmarinic
Blomia tropicalis extract (Bt)-immunized and challenged mice. (A) number of leukocytes in
EPO in the BAL; (D) levels of EPO in lung homogenates. Groups: Control, vehicle-treated an
Og100, Bt-sensitized and 25, 50 or 100 mg/kg of Og-treated mice, respectively; Bt/RA2; Bt/RA
Dex, Bt-sensitized and challenged, and Dex-treated mice. Columns represent the mean valu
from the means. pb0.05 vs control; ### p b0.001 vs control; * p b0.05, ** p b0.01, and *** p3. Results
3.1. Rosmarinic acid is present in the methanolic extract of O. gratissimum
leaves
Fig. 2 shows the chromatogram of the methanolic extract of Og
leaves (Fig. 2A), a RA solution (Fig. 2B) and an hexane extract of Og
leaves (Fig. 2C), demonstrating the separation of a compound in the
methanolic extract with the same retention time of RA in the stan-
dard sample (Fig. 2A and B). The estimated percentage of RA in the
Og methanolic extract was 0.21% (based on peak area). On the other
hand, the chromatogram of the hexane extract of Og (Fig. 2C) showed
no RA characteristic peak, indicating the absence of the compound in
that extract. Due to that, the immunopharmacological parameters
were performed using the methanolic extract of Ocimum gratissimum
leaves (coded thereafter as just Og).
3.2. Treatment with O. gratissimum methanolic extract and rosmarinic
acid reduces the Bt-induced BAL eosinophilia
To assess the effects of Og and RA on the eosinophilic exudate in
BAL of the Bt-sensitized and challenged mice, the presence of cells
in the BAL was assessed 24 h after the last challenge. Bt-challenged
mice displayed a signiﬁcant increase of both total cells and eosino-
phils in relation to the control group (pb0.001; pb0.05, respectively;
Fig. 3A and B). Oral administration of 100 mg/kg of Og, daily and 1 h
after the Bt challenges, signiﬁcantly suppressed the number of eosin-
ophils and total inﬂammatory cells, in relation to the untreated Bt-
immunized and challenged mice (pb0.01; Fig. 3A and pb0.05;
Fig. 3B, respectively). Oral administration of 50 mg/kg of Og sup-
pressed the number of eosinophils (pb0.05; Fig. 3B), but did not
modify the number of total inﬂammatory cells. The intraperitonealacid (RA) in the numbers of inﬂammatory cells, mainly eosinophils, in the airways of
the bronchoalveolar lavage (BAL); (B) number of eosinophils in the BAL; (C) levels of
imals; Bt, Bt-sensitized and challenged, and vehicle-treated mice; Bt/Og25; Bt/Og50; Bt/
20; Bt/RA200, Bt-sensitized and 2, 20 or 200 mg/kg of RA-treated mice, respectively; Bt/
es of the results obtained from six animals, and error bars represent the standard error
b0.001 vs Bt group. ANOVA–Tukey.
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press the number of total inﬂammatory cells (pb0.001; Fig. 3A) and
eosinophils (pb0.05; Fig. 3B). The groups Bt/Og25, Bt/RA2 and Bt/
RA20 did not show any signiﬁcant change in cellular levels in the
BAL. As expected, the administration of 3 mg/kg of Dex signiﬁcantly
suppressed the number of eosinophils and total inﬂammatory cells
(pb0.01; Fig. 3A and B).3.3. Treatment with O. gratissimum methanolic extract and rosmarinic
acid reduces eosinophil peroxidase levels in BAL and lungs
The sensitization of the animals with Bt produced a signiﬁcant in-
crease of EPO activity in the BAL (pb0.001) and in the lungs (pb0.01)
when compared to the control group (Fig. 3C and D). Treatment with
O. gratissimummethanolic extract only at a dose of 100 mg/kg or with
200 mg/kg of RA decreased EPO activity in both BAL (pb0.01) and
lung tissue (pb0.05) of Bt-immunized and challenged mice (Fig. 3C
and D). As expected, the treatment with 3 mg/kg of Dex decreased
EPO activity in both BAL (pb0.05) and lung tissue (pb0.001) of Bt-
immunized and challenged mice (Fig. 3C and D).Fig. 4. Effect of treatment with O. gratissimummethanolic extract and rosmarinic acid (RA) o
were stained with periodic acid-Schiff (magniﬁcation×200). (A) Lung section from a contr
treated mice; (C) Lung section from a Bt-immunized and challenged, O. gratissimum met
RA-treated mice; (E) Lung section from a Bt-immunized and challenged, Dex-treated mice
the mean of inﬂammatory area index of 6 mice, and the vertical bars represent the standard3.4. Treatment with O. gratissimum methanolic extract and rosmarinic
acid ameliorates the pathological changes of Bt-immunized animals
Histological evaluation of lung tissue revealed typical pathologic
features of allergic asthma in the Bt-immunized mice, characterized
by numerous inﬂammatory cells, including eosinophils, inﬁltrated
around the bronchioles (Fig. 4B). Treatment with 100 mg/kg of O. gra-
tissimum methanolic extract (Fig. 4C), 200 mg/kg of RA (Fig. 4D) and
Dex (Fig. 4E) markedly reduced the inﬂammatory cell inﬁltration
within the peribronchiolar and perivascular regions. The reduction
of inﬂammation was conﬁrmed by quantiﬁcation of inﬂammatory
area (pb0.001; Fig. 4F).
3.5. Treatment with O. gratissimum methanolic extract and rosmarinic
acid reduces the amount of mucus in the airways
To evaluate airway hypersecretion of mucus and goblet-cell hy-
perplasia, lung sections were stained with PAS. Mucus production
was signiﬁcantly induced in the airway of Bt-immunized and chal-
lenged mice (Fig. 5B). Treatment with 100 mg/kg of O. gratissimum
methanolic extract (Fig. 5C), 200 mg/kg of rosmarinic acid (Fig. 5D)n the production of mucus in the lung tissue of mice sensitized with Bt antigen. Sections
ol, saline-treated mice; (B) Lung section from a Bt-immunized and challenged, saline-
hanolic extract-treated mice; (D) Lung section from a Bt-immunized and challenged,
. (F) Quantiﬁcation of lung inﬂammation. Scale bar, 100 μm. Each column represents
deviation of the mean. ###pb0.001 vs control; ***pb0.001 vs Bt group, ANOVA–Tukey.
Fig. 5. Effect of treatment with O. gratissimummethanolic extract and rosmarinic acid (RA) on the production of mucus in the lung tissue of mice sensitized with Bt antigen. Sections
were stained with periodic acid-Schiff (magniﬁcation×200). (A) Lung section from a control, saline-treated mice; (B) Lung section from a Bt-immunized and challenged, saline-
treated mice; (C) Lung section from a Bt-immunized and challenged, 100 mg/kg of O. gratissimummethanolic extract-treated mice; (D) Lung section from a Bt-immunized and chal-
lenged, 200 mg/kg of RA-treated mice; (E) Lung section from a Bt-immunized and challenged, Dex-treated mice. (F) Mucus Index in the bronchi. Scale bar, 100 μm. Each column
represents the mean of the mucus indexes of 6 mice, and the vertical bars represent the standard deviation of the mean. ###pb0.001 vs control; *pb0.05, **pb0.01 vs Bt group,
ANOVA. Arrows indicate the presence of mucus.
131R.S. Costa et al. / International Immunopharmacology 13 (2012) 126–134and Dex (Fig.5E) markedly suppressed mucus secretion in the lung
tissue. The reduction of mucus production was conﬁrmed by quanti-
ﬁcation of mucus (Bt/RA200, pb0.05; Bt/Og100 and Bt/Dex, pb0.01;
Fig. 5F).
3.6. Treatment with rosmarinic acid and with O. gratissimum methanolic
extract does not change the levels of Bt-speciﬁc IgE antibodies in the sera
of Bt-immunized mice
Fig. 6 shows the levels of anti-Bt IgE antibodies in the sera of O.
gratissimum methanolic extract- and RA-treated, Bt-immunized mice.
Bt-immunized mice produced higher levels of speciﬁc IgE antibodies
than control (pb0.01). However, treatment with Og or RA, at tested
doses, as well as the Dex did not reduce the IgE antibody levels.
3.7. Treatment with O. gratissimum methanolic extract and rosmarinic
acid reduces levels of IL-4 in the BAL of Bt-immunized mice
To determine the possible mechanisms associated with the Og and
RA effects in airway inﬂammation, levels of the T-helper type 2 (Th2)
cytokine, IL-4 were evaluated. Levels of IL-4 in the BAL were higher in
Bt-immunized and challenged mice than in the control group(pb0.05). The treatment with 50 or 100 mg/kg of O. gratissimum
methanolic extract (pb0.05), 20 mg/kg (p b0.01) or 200 mg/kg
(pb0.001) of rosmarinic acid and Dex (pb0.001) led to signiﬁcant re-
ductions in levels of this Th2 cytokine in the BAL of Bt-immunized an-
imals in relation to those of untreated, Bt-immunized animals (Fig. 7).
4. Discussion
The inﬂammatory response to allergens in the asthmatic lung is a
consequence of inﬁltration of the airway wall by inﬂammatory cells,
especially eosinophils and is associated with the increased expression
of several inﬂammatory proteins in lung tissue, including cytokines,
such as IL-4 [21]. The resolution of inﬂammation is an essential pro-
cess for the establishment of appropriate host responses and the re-
turn to homeostasis [22].
The present study was conducted using a murine model of aller-
gic airway disease induced by the sensitization to a common aller-
gen, the B. tropicalis mite, which was previously characterized by
our research group as leading to an increased number of eosinophils
in the BAL ﬂuid, to a marked inﬂux of inﬂammatory cells into the
lung around blood vessels and airways, and to airway luminal nar-
rowing especially in A/J mice, the most sensitive to Bt amongst the
Fig. 6. Levels of anti-Blomia tropicalis extract (Bt) IgE antibodies in Bt-immunized mice
and treated with methanolic extract of O. gratissimum and rosmarinic acid. Antibody
levels were measured by indirect ELISA. Control (sensitized and treated animals with
vehicle); Bt (Bt-challenged mice and treated with vehicle), Bt/Og25; Bt/Og50;
Bt/Og100, Bt-sensitized and 25, 50 or 100 mg/kg of Og-treated mice, respectively;
Bt/RA2; Bt/RA20; Bt/RA200, Bt-sensitized and 2, 20 or 200 mg/kg of RA-treated mice,
respectively; Bt/Dex, Bt-sensitized and challenged, and Dex-treated mice. Columns
represent the mean values of the results obtained from six animals, and error bars rep-
resent the standard error from the means. ##pb0.01 vs control. ANOVA–Tukey.
Fig. 7. Effect of the treatment with Og methanolic extract and rosmarinic acid on the
levels of IL-4 in the BAL of Bt-challenged mice A/J. IL-4 quantiﬁcation was done by
sandwich ELISA. Control (vehicle-treated animals); Bt Bt-sensitized and challenged,
and vehicle-treated mice;, Bt/Og25; Bt/Og50; Bt/Og100, Bt-sensitized and 25, 50 or
100 mg/kg of Og-treated mice, respectively; Bt/RA2; Bt/RA20; Bt/RA200, Bt-sensitized
and 2, 20 or 200 mg/kg of RA-treated mice, respectively; Bt/Dex, Bt-sensitized and
challenged, and Dex-treated mice. Columns represent the mean values of the results
obtained from six animals, and error bars represent the standard error from the
means. #pb0.05 vs control. * pb0.05, **pb0.01 and *** pb0.001 vs Bt group.
ANOVA–Tukey.
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allergic effect of an O. gratissimum extract, and the polyphenolic
compound rosmarinic acid, in an experimental model of airway
and lung inﬂammation induced by a clinically relevant aeroallergen.
O. gratissimum extracts have been shown to contain large amounts
of polyphenolic compounds (ﬂavonoids, stilbenes, phenolic acids and
others), including RA [12,23]. Polyphenols have been shown to exert
antiallergic, antiinﬂammatory, and bronchodilatory effects, by reduc-
ing the levels of inﬂammatory cytokines, chemokines, eosinophils
and anti-allergen antibodies [24–26]. To assess the presence and the
amount of RA in the Og used in this study, we analyzed the extract
by HPLC, which allowed us to conﬁrm the presence of RA in the Og
(methanolic extract), but not in the hexane extract. The estimated
amount of RA in the methanol extract was 0.2%, corroborating a pre-
viously published study [12].
An ethnopharmacology survey conducted by our research group,
describing plant species used in the folk medicine to treat allergies
[7], identiﬁedO. gratissimum as one of these plants. To date, however,
no scientiﬁc study has conﬁrmed this activity. Some biological activ-
ities exerted by O. gratissimum are attributed to its polyphenols that
are present in high quantities in the plant [12]. In the present study,
the treatment with Og and RA in Bt-sensitized and challenged mice
resulted in a signiﬁcant inhibition of airway and lung stroma inﬂam-
mation, characterized by reduction in: (i) numbers of total inﬂam-
matory cells and eosinophils in BAL and lung; (ii) inﬂammatory cell
inﬁltration in the peribronchiolar and perivascular pulmonary re-
gion; (iii) presence of mucus inside airways; (iv) levels of IL-4 in
the BAL.
The administration of RA orally (100 mg/Kg) was not able to in-
hibit the inﬂammatory process (data not shown). This can be
explained by the fact that 99% of this compound is degraded by intes-
tinal bacterial ﬂora [19]. Thus, the Og anti-inﬂammatory activity ob-
served in this study is not attributed to RA exclusively, but in fact
we believe that other compounds that may act synergistically could
be responsible for its observed antiallergic effects.
The anti-inﬂammatory and immunomodulatory activities of RA
has been ascribed to its inhibition of the lipoxygenase and cyclooxy-
genase pathways, interference with the complement cascade [27]
and, mainly, the suppression of T-cell antigen receptor signaling
[28]. These activities may explain, at least in part, the airway antial-
lergic activity of RA observed in this study.Eosinophilia is a relevant pathological feature of allergic diseases,
contributing to airway damage through the release of several cyto-
toxic mediators including EPO, eosinophil-derived major basic pro-
tein, eosinophil cationic protein and bronchoconstrictor mediators,
such as leukotriene C4 (LTC4) [29]. Accordingly, the increased pres-
ence of eosinophils and their secreted products in the asthmatic
lungs often correlates with severity and exacerbation of disease
[30]. Additionally, the eosinophils have been shown to be a source
of cytokines that are directly involved in the development of type I
hypersensitivity, including IL-4, IL-5, and IL-13, suggesting that
they have important roles in the immunopathology of allergic asth-
ma [31,32].
Several studies attribute the antiallergic property of natural prod-
ucts to their ability to reduce the eosinophilic inﬂammatory process
[29,33,34]. For example, an extract of P. frutescens, a species belonging
to the same taxonomical family of O. gratissimum, attenuates allergic
airway inﬂammation by inhibiting Th2 cytokines and eosinophil inﬁl-
tration into the airways. This activity was attributed to the RA that
was present in that extract despite the fact that the effect of pure ros-
marinic acid was not evaluated and thus the contribution of other ex-
tract constituents cannot be ruled out [26]. Different mechanisms
have been proposed to explain the reduction in lung eosinophilia in-
duced by plant-derived products, such as the suppression of the syn-
thesis and inhibition of the effects of eosinophil survival factors, and
the direct induction of eosinophil apoptosis [35].
In order to explore the mechanism whereby Og and RAmodulated
eosinophils inﬁltration and activation we investigate the effect of
these drugs on IL-4 production. Eosinophils activates cytokines and
chemokines such as IL-4, IL-5 and eotaxin [36] which are involved
in events related with airway inﬁltration and eosinophil activation,
IgE production, and mucus secretion [37,38].
Increased mucus production by goblet cells in the airway epitheli-
um is associated with airway inﬂammation and asthma. The data pre-
sented here demonstrated that Og and RA reduced the amount of
mucus present in the airways in the Bt-induced experimental model
of airway inﬂammation. IL-13 and IL-4 play an important role in the
production of mucus [39]. Thus, the decrease in mucus in the airways
of mice treated with Og and RA may be due to the inhibition of Th2
cytokines by these agents, which is supported by the reduced IL-4
levels that were found in the BAL of the treated mice. IL-4 promotes
133R.S. Costa et al. / International Immunopharmacology 13 (2012) 126–134the recruitment of eosinophils and stimulates B lymphocytes to
synthesize IgE [40] thus, the reduction of this cytokine may exert an
important antiasthmatic effect. High anti-allergen IgE antibody levels
in the serum or BAL have been associated with airway hyper-
responsiveness in both adults and children with asthma as well as
contributing to the severity of the disease [41]. These antibodies acti-
vate events related to eosinophil and mast cell degranulation [42]. In
this study, treatment with Og and RA did not signiﬁcantly reduced
the levels of B. tropicalis-speciﬁc IgE and this might be explained by
the fact that although the active inﬂammatory response and cell mi-
gration are modulated, the IgE levels are already up-regulated in
allergic animals. Thus, due to the half-life of IgE antibody its detection
is not possible in a short-term protocol like ours, even when animals
were treated with Dex. A possible effect of these drugs in the produc-
tion of B. tropicalis-speciﬁc IgE antibodies should be assessed in a
chronic experimental model of B. tropicalis-induced respiratory al-
lergy that has a longer duration of treatment and evaluation time
points.
In addition, based on the fact that RA is more active in reducing
EPO activity in BAL rather than in lungs, we speculate that besides
IL-4, RA may also modulate other cytokines and/or chemokines
that can regulate the eosinophil migration from the lung tissue to
the alveoli. This might reﬂect less eosinophils in the bronchoalveo-
lar lavage and consequently less EPO.
The main limitation of this study was using only one mice strain
and one common allergen for the sensitization protocol. We be-
lieve that other strains (not yet evaluated) or even other common
sensitizing agent such as Dermatophagoides pteronissinus could be
useful in future studies to investigate action and mechanisms of
anti-allergic drug candidates. Another limitation of the study was
related to the lung inﬂation protocol used as ﬁxed-volume inﬂation
rather than ﬁxed-pressure inﬂation.
However, we believe that the results presented herein, obtained using
an experimental model clinically relevant to human beings strongly sup-
port the potential usefulness of Og and RA as anti-inﬂammatory agents
for the treatment of allergic asthma. In addition, these ﬁndings justify
the need of further experiments to elucidate themolecularmechanisms
underlying the Og and RA immunomodulatory effects.
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